Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exemestane + seribantumab
- Development stage
- Unknown
- Lead developer
- Elevation Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Exemestane + seribantumab is an investigational combination therapy studied primarily in hormone receptor-positive, HER2-negative metastatic breast cancer. Exemestane is a steroidal aromatase inhibitor that irreversibly blocks the conversion of androgens to estrogens, thereby reducing estrogen levels and limiting the growth of estrogen-dependent tumors[4]. Seribantumab is a fully human IgG2 monoclonal antibody targeting the human epidermal growth factor receptor 3 (HER3/ErbB3). It antagonizes HER3 signaling by blocking heregulin (NRG1) binding, inhibiting downstream PI3K-AKT pathway activation and tumor cell proliferation[1][5][6]. The combination was evaluated in phase 2 clinical trials for postmenopausal women with ER/PR+, HER2– metastatic breast cancer. Exploratory analyses suggest patients with detectable HRG mRNA may benefit most from this regimen[2][3].
- Other names
- MM-121 + Aromasinseribantumab + exemestane
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)CYP19A1 (Aromatase)
Beyond the preview
Go deeper on exemestane + seribantumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exemestane + seribantumab.